ENVB Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
3.0M
+85.4%
1.6M
-25.6%
2.2M
+17.1%
1.9M
-25.6%
2.5M
R&D
1.4M
+291.7%
346.0K
-7.0%
372.2K
-7.5%
402.4K
-68.1%
1.3M
SG&A
1.6M
+30.8%
1.2M
-29.9%
1.8M
+24.5%
1.4M
+17.4%
1.2M
Operating Income
-3027441
-85.4%
-1633170
+25.6%
-2193923
-17.1%
-1873943
+25.6%
-2519049
EBITDA
-2990615
-87.4%
-1595930
+25.9%
-2154438
-17.5%
-1833574
+26.0%
-2479069
Net Income
-3027733
-85.4%
-1633473
+25.6%
-2194171
-17.1%
-1873669
+25.6%
-2519181
EPS (Basic)
$-0.76
+29.6%
$-1.08
+82.4%
$-6.13
+43.3%
$-10.81
+7.2%
$-11.65
EPS (Diluted)
$-0.76
+29.6%
$-1.08
+82.4%
$-6.13
+43.3%
$-10.81
+7.2%
$-11.65
Shares (Diluted)
4.0M
+164.0%
1.5M
+129.0%
659.5K
+110.5%
313.2K
+44.8%
216.3K
Enveric Biosciences (ENVB) โ€” Financials